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Résumé 
La résistance bactérienne aux aminoglycosides est principalement la conséquence de l'action 
d'enzymes qui modifient chimiquement ces antibiotiques et les empêchent ainsi de se lier à 
leur cible. Pour contourner ce mécanisme, une possibilité intéressante consisterait à bloquer 
l'action de ces enzymes aux moyen d'inhibiteurs sélectifs. Nous décrivons une approche 
rationnelle utilisant la spectroscopie RMN pour isoler des ligands spécifiques de ces enzymes. 
En utilisant des techniques de transfert d'aimantation, l'identification de contacts entre des 
pharmacophores élémentaires et la cible protéique permet de guider de manière précoce le 
processus d'amélioration des touches obtenues.  
Abstract 
Bacterial resistance to aminoglycosides is mainly the result of enzyme-catalysed chemical 
modifications of these antibiotics, which prevents their binding to their target. In order to 
circumvent this mechanism, an attractive possibility would be to block these enzymes, using 
selective inhibitors. This work describes a rational strategy aimed at isolating specific ligands 
of these enzymes, using NMR spectroscopy. Using magnetisation transfer techniques, the 
identification of contacts between elementary pharmacophores and the protein target allows 
the guidance of hit improvement from a very early stage. 
 
Mots-clés : RMN en flux, criblage, antibiotique, désoxystreptamine, fluorescence. 
Keywords : flow-injection NMR, screening, antibiotic, deoxystreptamine, fluorescence 
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1. Introduction 
Aminoglycosides are broad-spectrum antibiotics which act by binding to the decoding site of 
ribosomal 16S RNA [1, 2], they are used with β-lactams in polytherapies against severe 
infections caused by gram-negative bacteria and staphylococci, mostly of nosocomial origin. 
Resistance to these antibiotics arise mainly through the action of aminoglycoside-modifying 
enzymes which catalyse the covalent addition of acetyl, phosphate or nucleotidyl groups onto 
amino or hydroxyl functions [3]. Among the modifying enzymes found in clinical strains, N-
6' aminoglycoside acetyl transferases (AAC(6')) are the most prevalent ones, accounting for 
50-75 % of the resistance phenotypes (their mechanism is shown in figure 1A). These have 
been classified in subfamilies (AAC(6')-I, AAC(6')-II, AAC(6')-III and AAC(6')-IV, see [2]), 
based on their specificity profile vs. the various clinically-used aminoglycosides (Gentamicin, 
Amikacin, Isepamicin…). This picture has recently been getting more complicated, as very 
broad spectrum variants have begun to emerge [4], which confer resistance to almost all 
aminoglycosides and are thus a serious threat to current therapies. 
In order to circumvent this problem, it would be desirable to either isolate new 
aminoglycosides which escape the current resistance mechanisms or to design specific 
inhibitors of their modifying enzymes. Up to now, however, progress in these two directions 
has been hampered by the difficulties of aminoglycoside chemistry. These result from the 
combination of two factors : the large number of functional groups and chiral centres in these 
molecules and their intrinsic symmetry (see for instance kanamycin, figure 1B) and in 
particular that of the central ring, 2-deoxystreptamine (2-DOS), a meso- compound. Synthetic 
routes to this compound are known but are still quite involved (reviewed in [5]) and attempts 
to replace it with alternate, simpler scaffolds have so far only been moderately successful [6]. 
There is thus a need for an efficient 2-DOS mimic, as a building block for aminoglycoside 
resistance enzyme inhibitors. The present work describes the identification of such a 
compound and of an NMR-based strategy to characterise derivatives of this molecule with 
improved affinities to one of the new extended-spectrum, clinical forms of AAC(6'), AA(6')-
Ib11 [4]. 
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2. Materials and Methods 
2.1 Enzyme expression and purification 
The enzyme used in this study is an extended-spectrum aminoglycoside 6' N-acetyl 
transferase of type Ib isolated from a clinical Salmonella strain [4]. A recombinant expression 
system was constructed by cloning the PCR-amplified DNA coding sequence in plasmid 
pET101, using the pET101/D-Topo expression kit (Invitrogen). The resulting recombinant 
plasmid encodes the 189 aminoacid subunit of AAC(6')-1b11 [4] under control of the T7 
transcription promoter. Expression of the protein was obtained after transformation of the 
plasmid into strain BL21Star (Invitrogen). Cells were grown at 37°C  in LB medium 
supplemented with ampicillin (100 mg/L) until turbidity reached an absorbance of 1.0 at 650 
nm. They were then induced by addition of 0.5 mM isopropyl-thiogalactoside (IPTG), 
incubation was then continued for two hours at 30°C. Bacteria were harvested by 
centrifugation, resuspended in 20 mM sodium phosphate pH 7.5 (buffer A) and lysed by 
sonication. Cell debris were removed by centrifugation and the crude extract was loaded on a 
Superdex G75 gel filtration column (2.6 x 60 cm, Amersham) equilibrated in buffer A. 
Fractions containing the overproduced enzyme were pooled and submitted to an ion-exchange 
chromatographic step : after loading on a Q-Sepaharose Hiload column (2.6 x 20 cm, 
Amersham) equilibrated in buffer A, the protein was eluted by applying a 0 to 500 mM linear 
NaCl gradient.  The pooled protein fractions were dialysed against 20 mM Tris-HCl pH 8.5 
and submitted to a second ion-exchange chromatographic step in this buffer. Except for the 
increased pH, it was identical to the first ion-exchange separation. After this step, the protein 
was homogeneous, as judged by SDS-gel electrophoresis. It was dialysed against 10 mM 
HEPES pH 7.0 and concentrated by ultrafiltration on a Centriprep cell (Amicon-Millipore). 
Yield was 7.5 mg of purified enzyme for a 1 litre culture. 
2.2 Ligands 
Kanamycin A sulphate was from Amersham-USB. Synthesis of compound 1 has been 
described [7], and that of 2 and 3 will be described elsewhere (Begis & Micouin, 
unpublished). Concentrated stock solutions (50 mM) were prepared in H20 from dry 
chlorhydrates (compounds 1, 2 and 3) or sulphate (Kanamycin) and the pH was adjusted to 
neutrality. 
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2.3 NMR Methods 
Spectra were recorded on a 600 MHz Bruker Avance spectrometer equipped with either a 
5 mm standard triple resonance inverse probe, or with a 3 mm triple resonance flow-injection 
probe connected to a LC215 Gilson pipetting robot (Bruker BEST system). All spectra were 
recorded in 20 mM sodium phosphate buffer (pH 7.0) prepared in 90% H2O/10% 2H2O (by 
volume) and the solvent resonance was suppressed by presaturation, excitation sculpting [8] 
or by gradient selection for heteronuclear experiments. Resonance assignments for kanamycin 
were obtained using a 50 mM sample in a 5 mm tube. 2D ROESY, DQF-COSY and [1H-13C] 
HSQC as well as a natural abundance 3D [1H-13C] TOCSY-HSQC were recorded. The latter 
experiment was required to unambiguously assign the severely overlapping sugar proton 
massif. All experiments were recorded at 25°C (298 K). Stereoselective assignments of the 
methylene protons of carbon 2 of both kanamycin and compound 1 were obtained by 
analysing the relative intensity of the ROESY transfers and J-couplings with protons 1 and 3 
(numbering as in figure 1). Assignments are indicated on figure 2. Ligand binding was 
monitored by the Saturation Transfer Difference (STD) [9] and/or the reverse NOE-pumping 
methods [10], using the flow-injection NMR system. Sample injection was as previously 
described [11], briefly, the ligand and the protein were mixed in a final volume of 180 μl of 
20 mM sodium phosphate pH 7.0 and put in 96-well plates. Final concentrations were 1 mM 
for the ligand and 50 μM for the protein. For STD experiments, band irradiation of the protein 
methyl massif (0.5 ppm) was performed for 2 seconds at a field strength of 80-100 Hz. For 
reverse NOE pumping, mixing times of 200 and 700 ms were used, in order to detect both 
strong and weak transfers. 
2.3 Biochemical affinity measurements 
Fluorescence measurements were performed in a Jasco FP6200 spectrophotofluorimeter 
equipped with a thermostated cell. The enzyme concentration was 80 nM in 1 mL of 20 mM 
sodium phosphate buffer pH 7.5. Increasing amounts of the ligands were iteratively added to 
the protein solution which was magnetically stirred. The intrinsic fluorescence of tryptophan 
residues was followed using an excitation wavelength of either 280 or 295 nm and an 
emission wavelength of 343 nm. All measurements were performed at 21°C. All points were 
measured in duplicate and the binding parameters were derived by iterative non-linear least 
square fitting to a single hyperbolic function [12]. Additional binding data was also obtained 
by equilibrium dialysis, using disposable microcells (DispoEquilibrium Dialyzer, Harvard 
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Biosciences, Hollington, USA). The enzyme compartment (75 μl) contained 200 μM of 
purified AAC(6')-Ib and the ligand compartment (75 μl) contained an equal concentration of 
compound 2, either with or without 200  μM of kanamycin A. After equilibration, relative 
ligand concentrations in the equilibrium dialysis cell compartments were monitored by UV 
spectrophotometry. Dissociation constants were estimated with Mathematica (Wolfram 
Research). 
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3. Results 
3.1 Design of an analogue of 2-deoxystreptamine 
The common core structure recognised by N-6' aminoglycoside acetyl transferases 
corresponds approximately to that of neamine (Figure 1A), i.e. a 6-glucosamine attached to a 
2-deoxystreptamine ring (2-DOS). Substituents attached to positions 5 and 6 (R1 and R2, 
figure 1A) appear not to be involved in interactions with these enzymes. This is confirmed by 
the crystal structure of AAC(6')-Iy complexed with ribostamycin [13] for which the R2 group 
is a ribose which lies in the solvent, making little if any contacts with the protein. This is in 
contrast with the 2-DOS ring which makes electrostatic interactions with the enzyme via its 
two amino groups and is stacked on aromatic side chains. Thus, any scheme for designing an 
inhibitor of AAC(6') must include 2-DOS or a structural analogue of it. However 2-DOS 
chemistry is quite difficult, making its direct use a serious challenge and we thus chose to try 
and replace it by similar, more accessible scaffold. The features which we found desirable for 
an analogue of 2-DOS in the context of AAC(6') inhibition were (i) a constrained cyclic 
structure which would allow stacking within the enzyme active site, (ii) a pair of amino 
groups with a geometry close to that of 2-DOS and (iii) an additional function for linking 6-
glucosamine or a similar group in an analogous geometry. We selected derivatives of trans, 
trans diamino-cyclopentanol (Figure 1C and figure 3) as these fulfilled the three above 
criteria, have no additional reactive groups apart from those strictly necessary, are no longer 
symmetrical and can be easily synthesized enantioselectively [7]. 
3.2 diamino-cyclopentanol binding to AAC(6')-Ib 
The binding of diamino-cyclopentanol (compound 1, figure 3) to AAC(6')-Ib was analysed 
and compared to that of kanamycin A, a natural substrate of the enzyme. As it is a very simple 
pharmacophore, one could expect it to have a significantly reduced affinity. We thus used 
NMR interaction screening, as this technique is able to detect weak interactions and provides 
information on the binding mode of the ligand. Both Saturation Transfer Difference (STD) 
and reverse NOE pumping experiments were used to evidence magnetisation transfer between 
the protein and specific protons from the ligand. Similar results were obtained with both 
techniques and a typical STD experiment is shown in figure 2. Two pieces of information can 
be derived from these approaches : observation of transferred magnetisation demonstrates that 
compound 1 binds efficiently to the enzyme. For both STD (figure 2) and NOE pumping (not 
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shown), a significantly stronger signal is observed for the axial proton located on carbon 2 
(figure 2, numbering as in figure 1). This indicates that kanamycin binds the enzyme with the 
amino face of 2-DOS in close contact with AAC(6')-Ib, a result which is in keeping with the 
crystal structure of the distantly related AAC(6')-Iy [13], and that compound 1 binds in a 
similar fashion, also with the two amino groups facing the enzyme surface. Equilibrium 
dialysis experiments confirmed that diamino-cyclopentanol derivatives such as compound 2 
do bind to AAC(6')-Ib, with a Kd in the 10-5 M range, and that this interaction is efficiently 
antagonised by kanamycin (not shown) and thus that binding is competitive. This experiment 
was performed with compound 2, as its concentration can be easily monitored by UV 
absorption. Overall, this strongly suggests that binding of diamino- cyclopentanol and its 
derivatives occurs at the same site and in the same orientation as that of 2-DOS in kanamycin. 
3-3 NMR provides qualitative information on AAC(6') ligand affinity. 
The above results show that compound 1 is indeed a simple scaffold that can mimic 
2-deoxystreptamine in the design of competitive inhibitors of AAC(6') enzymes. Because of 
its small size, its binding affinity is however limited and it failed to significantly inhibit the 
enzyme in standard acetylation assays (not shown). Nevertheless, it provides a specific anchor 
point on the enzyme, from which more complex molecules can be constructed, by linking 
additional pharmacophores to improve the affinity. Several derivatives of compound 1 were 
thus synthesised by substituting the hydroxyl group with different types of linkages. Two such 
compounds with aryl groups replacing the 6-glucosamine group are shown in figure 3. 
Because of the lack of an efficient enzymatic test at this early stage of inhibitor design, we 
wanted to investigate whether NMR interaction screening techniques such as reverse NOE 
pumping could provide qualitative information on the binding mode and affinity of these 
bipartite ligands of AAC(6'). We chose compounds 2 and 3 (figure 3) since their NMR spectra 
show completely separate signals for the cyclopentane moiety and the aromatic ring, on either 
side of the spectral window (figure 4). It was expected that for all such ligands, the constant 
cyclopentane ring would bind in most cases, whereas, depending on the nature of the linkage 
and of the substituent, the other moiety would either fit into the active site or be rejected 
outside the protein. In the former case, NOE transfer is expected to occur for both parts of the 
molecule, whereas in the latter, transfer would only occur for the cylcopentane moiety, and 
not for the substituent. The result of such an experiment for compounds 2 and 3 is shown in 
figure 4. Compound 2 does show a contact between an aromatic proton and the protein 
(emphasized by a black circle on figure 4), whereas compound 3 does not show any 
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significant transfer. This suggests that the aromatic ring of compound 2 slips at least in part 
into the active site, whereas that of compound 3 cannot, possibly because of the different 
linkage. In order to see whether these observations could be correlated with the affinity of 
these two ligands for the enzyme, fluorescence titrations were performed. We indeed 
observed that ligand binding induces a large quenching of the intrinsic fluorescent signal of 
tryptophan residues (50-70 % quenching). This was not unexpected as AAC(6')-I enzymes 
share conserved tryptophan residues within their active sites, on which the 2-DOS ring of the 
substrate was observed to stack [13]. The resulting fluorescence data were compared to that 
obtained with the parent compound 1, in order to see whether the substituents provided either 
an improvement or a loss of affinity, and this is shown on figure 5. The three compounds 
indeed showed differential affinities, with calculated dissociation constants of 41 ± 3 μM for 
compound 1, 23 ± 2 μM for compound 2 and 57± 6 μM for compound 3. This correlates very 
well with the NMR results, as the additional contact zone observed with 2 indeed results in a 
two-fold improvement of the affinity, whereas the small loss observed with 3 can probably be 
ascribed  to a steric hindrance of the substituent which apparently does not fit into the protein. 
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4. Conclusion 
This work describes an iterative strategy for designing ligands of AAC(6'), which can be used 
for isolating inhibitors of these antibiotic resistance enzymes. It is based on the 
characterization of a primary pharmacophore showing specific binding, the affinity of which 
is subsequently improved by "decorating" it with additional functional groups. Both stages of 
this approach rely on the use of NMR to detect and characterize ligand interactions. In the 
first step, NMR was used to reveal weak but specific interactions of simple compounds which 
cannot be reliably detected by enzymatic tests. It also allowed to control that they were likely 
to bind in the correct orientation. In a latter stage, the present study shows that the NMR 
approach allows a qualitative ranking of the various substituents of the anchoring 
pharmacophore, diamino cyclopentanol. This can provide a rationale for the early guidance of 
medicinal chemists and thus could significantly speed up the discovery process. This is 
particularly interesting for those molecules which cannot be easily tested by fluorimetric 
techniques. A number of the derivatives of compound 1 which were originally synthesized 
indeed either showed a significant fluorescent background or exhibited a significant UV 
absorbance at the typical tryptophan excitation wavelengths, which prevented their direct 
analysis by fluorescence methods. Those molecules can however be productively tested by the 
NMR approach. Using the above strategy, ligands with affinities in the micromolar range 
have presently been isolated, and all of these derive from an original and easily accessible 
scaffold. This is already significant and further application of this strategy should in principle 
allow for the identification of inhibitors with higher affinities. Its combination with robotised 
flow-injection NMR makes it attractive for a medium scale screening approach of 
aminoglycoside resistance enzyme inhibitors. 
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Figure Legends 
Figure 1 : (A) Aminoglycoside acetylation reaction catalysed by AAC(6') enzymes. Shown is 
the common core structure which corresponds to neamine. Amines are shown in protonated 
form, as they usually are at physiological pH. CoA stands for Coenzyme A. R1 is either –OH 
or –NH2. Aminoglycosides are either substituted at R2 or R3, yielding the neomycin and 
kanamycin family, respectively. (B) Structure of kanamycin A, showing the quasi-symmetry 
about the median plane of  deoxystreptamine ring. (C) Generic structure of the 
deoxystreptamine analogues used in this study. 
 
Figure 2 : STD analysis [9] of the binding of kanamycin (bottom) and the deoxystreptamine 
analogue 1 (top) to AAC(6')-Ib11. Assignments of the various protons are indicated on the 
reference spectra (Ref). The boxed peaks correspond to protons of the CH2 group located in 
between the two amino groups. In both cases, the shaded box corresponds to the axial proton 
of this methylene group and shows the strongest STD signal. 
 
Figure 3 : Structure of the AAC(6') ligands used in this study. These were racemic mixtures 
of the two possible enantiomers. 
 
Figure 4 : Interaction of ligands 2 (top) and 3  (bottom) with AAC(6') -Ib11. Shown are 
reference proton spectra (Ref) immediately above the corresponding reverse NOE pumping 
experiments (NOE) which show the intermolecular NOE transfer between the ligands and the 
protein [10]. Aliphatic resonances (1.5-5.5 ppm) belong to the cyclopentane ring, whereas the 
leftmost protons (6.5-8.0 ppm) correspond to the aromatic ring substituent.  
 
Figure 5 : Fluorescence titration of the binding of the various ligands to AAC(6')-Ib. The 
fluorescence data was normalized, so that the initial signal was set to 100 % and the fully 
quenched signal extrapolated at infinite ligand concentration corresponded to 0 %. Individual 
data points are shown on top of the fitted curves. The titration of the reference compound 1 is 
shown with solid circles and a thick line. Data corresponding to compounds 2 and 3 are 
indicated by diamonds and a thin line, or by triangles and a dashed line, respectively. 
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